Cargando…

Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling

BACKGROUND: To assess antivascular effects, and evaluate clinically translatable magnetic resonance imaging (MRI) biomarkers of tumour response in vivo, following treatment with vanucizumab, a bispecific human antibody against angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A)....

Descripción completa

Detalles Bibliográficos
Autores principales:	Baker, Lauren CJ, Boult, Jessica KR, Thomas, Markus, Koehler, Astrid, Nayak, Tapan, Tessier, Jean, Ooi, Chia-Huey, Birzele, Fabian, Belousov, Anton, Zajac, Magdalena, Horn, Carsten, LeFave, Clare, Robinson, Simon P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5023775/ https://www.ncbi.nlm.nih.gov/pubmed/27529514 http://dx.doi.org/10.1038/bjc.2016.236

Ejemplares similares

Pre-clinical imaging of transgenic mouse models of neuroblastoma using a dedicated 3-element solenoid coil on a clinical 3T platform
por: Almeida, Gilberto S, et al.
Publicado: (2017)

Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1
por: Bertrand, Y, et al.
Publicado: (2011)

The endogenous anti-angiogenic VEGF isoform, VEGF(165)b inhibits human tumour growth in mice
por: Rennel, E S, et al.
Publicado: (2008)

Migration-promoting role of VEGF-C and VEGF-C binding receptors in human breast cancer cells
por: Timoshenko, A V, et al.
Publicado: (2007)

VEGF(165)b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy
por: Varey, A H R, et al.
Publicado: (2008)

Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity
por: Stish, B J, et al.
Publicado: (2009)

TRAIL inhibits angiogenesis stimulated by VEGF expression in human glioblastoma cells
por: Cantarella, G, et al.
Publicado: (2006)

VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma
por: Beckermann, B M, et al.
Publicado: (2008)

Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma
por: Gammons, M V, et al.
Publicado: (2014)

The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumour activity while maintaining vascular function
por: Baker, L C J, et al.
Publicado: (2012)

COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer
por: Timoshenko, A V, et al.
Publicado: (2006)

Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody
por: Osada, T, et al.
Publicado: (2010)

The role of tumour-derived iNOS in tumour progression and angiogenesis
por: Kostourou, V, et al.
Publicado: (2011)

Hypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas
por: Yoon, C, et al.
Publicado: (2015)

A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer
por: Wentink, Madelon Q, et al.
Publicado: (2016)

Tumour biomechanical response to the vascular disrupting agent ZD6126 in vivo assessed by magnetic resonance elastography
por: Li, J, et al.
Publicado: (2014)

hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines
por: Masi, A, et al.
Publicado: (2005)

Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells
por: Garvin, S, et al.
Publicado: (2005)

False-negative MRI biomarkers of tumour response to targeted cancer therapeutics
por: Boult, J K R, et al.
Publicado: (2012)

Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-β and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation
por: Vlahovic, G, et al.
Publicado: (2006)

Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalisation without inducing empty basement membrane sleeves in xenograft tumours
por: Coutelle, O, et al.
Publicado: (2015)

VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide
por: Orlandi, P, et al.
Publicado: (2013)

Evaluation of the Response of Intracranial Xenografts to VEGF Signaling Inhibition Using Multiparametric MRI
por: Boult, Jessica K.R., et al.
Publicado: (2017)

Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells
por: Carbajo-Pescador, S, et al.
Publicado: (2013)

Multiple mechanisms underlie defective recognition of melanoma cells cultured in three-dimensional architectures by antigen-specific cytotoxic T lymphocytes
por: Feder-Mengus, C, et al.
Publicado: (2007)

PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype
por: Catalano, Onofrio Antonio, et al.
Publicado: (2017)

Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model
por: Hermes, M, et al.
Publicado: (2008)

Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations
por: Bramley, M, et al.
Publicado: (2006)

Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment
por: Zhu, Winston M, et al.
Publicado: (2023)

Identification of biomarkers for the antiangiogenic and antitumour activity of the superoxide dismutase 1 (SOD1) inhibitor tetrathiomolybdate (ATN-224)
por: Doñate, F, et al.
Publicado: (2008)

Interactions between microenvironment and cancer cells in two animal models of bone metastasis
por: Blouin, S, et al.
Publicado: (2008)

Collagenase-2 (matrix metalloproteinase-8) plays a protective role in tongue cancer
por: Korpi, J T, et al.
Publicado: (2008)

Immunisation with ‘naïve’ syngeneic dendritic cells protects mice from tumour challenge
por: Grimshaw, M J, et al.
Publicado: (2008)

CD44(+)CD24(−) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis
por: Hurt, E M, et al.
Publicado: (2008)

Regulation of apoptosis-inducing factor-mediated, cisplatin-induced apoptosis by Akt
por: Yang, X, et al.
Publicado: (2008)

Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status
por: Akashi, Y, et al.
Publicado: (2008)

20(S)-25-methoxyl-dammarane-3β, 12β, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action
por: Wang, W, et al.
Publicado: (2008)

Double inhibition of XIAP and Bcl-2 axis is beneficial for retrieving sensitivity of renal cell cancer to apoptosis
por: Bilim, V, et al.
Publicado: (2008)

Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
por: Bianco, R, et al.
Publicado: (2008)

Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma
por: Campbell, L, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_jntukrkqtcmsgufoote3jthmba